By-health (300146) Fundamentals 2026 — P/E 23.3x, Revenue Analysis | SniperIQ
By-health (300146) is a CN-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥17.1B, trading at ¥10.13 on the SHZ. This SniperIQ fundamentals page covers By-health's valuation (P/E 23.3x, P/B 1.5x), profitability (net margin 11.5%), revenue (¥6.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is By-health's market cap?
By-health (300146) has a market capitalization of approximately ¥17.1B, trading at ¥10.13 on the SHZ. Market cap moves with the live share price.
What is By-health's P/E ratio?
By-health's trailing twelve-month P/E ratio is 23.3x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is By-health?
By-health runs a net profit margin of 11.5%, a gross margin of 67.3%, and an operating margin of 12.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does By-health generate?
By-health reported revenue of ¥6.2B for fiscal year 2025, with net income of ¥782M and earnings per share (EPS) of 0.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does By-health pay a dividend?
By-health offers a trailing dividend yield of about 4.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is By-health financially healthy?
By-health carries a debt-to-equity ratio of 0.09x and a current ratio of 3.38x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is By-health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For By-health (300146) the key facts are: market cap ¥17.1B, P/E 23.3x, revenue ¥6.2B, 52-week range 8.87-13.2. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track By-health's full fundamentals live
Get By-health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.